HeadNeck Banner
Keytruda Logo

Head and Neck Cancer Overview

This page is approved only for HCPs in Gulf (UAE, Kuwait, Oman, Bahrain & Qatar).

R/M HNSCC indication approved in UAE1

  • In combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC
  • As a single agent for the first line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.

As a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum- containing chemotherapy.

R/M HNSCC indication approved in Qatar2

For the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.

R/M HNSCC indication approved in Kuwait, Bahrain & Oman3

For the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.

References:

  1. Keytruda USPI June 2019
  2. Keytruda USPI April 2019
  3. Keytruda USPI August 2018

Gulf (UAE, Oman, Kuwait, Bahrain & Qatar):
AE-KEY-00024 | Expiry: 31-Dec-2019